EW
SMMT icon

Evoke Wealth’s Summit Therapeutics SMMT Stock Holding History

Evoke Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$190K – 543
2026
Q1 		$190K Hold
10,000
– – ﹤0.01% 678
2025
Q4 		$175K Hold
10,000
– – ﹤0.01% 647
2025
Q3 		$207K Hold
10,000
– – ﹤0.01% 603
2025
Q2 		$213K Buy
+10,000
New +$228K ﹤0.01% 551

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Evoke Wealth's SMMT Position: Q2 2026 in Review

Evoke Wealth sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 10,668 shares — an estimated $202K sold.

Evoke Wealth first reported a position in SMMT in Q2 2021 and held it in 13 quarters. The position peaked at $329K in Q3 2024. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Evoke Wealth reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Evoke Wealth sold 10,668 Summit Therapeutics shares in Q2 2026, an estimated $202K.
  • Evoke Wealth first reported a position in Summit Therapeutics in Q2 2021 and held it in 13 quarters.
  • Evoke Wealth's Summit Therapeutics position peaked at $329K in Q3 2024.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Evoke Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.